slide1 n.
Download
Skip this Video
Download Presentation
Richard C. “Mort” Wasserman, MD, MPH Professor of Pediatrics, University of Vermont

Loading in 2 Seconds...

play fullscreen
1 / 13

Richard C. “Mort” Wasserman, MD, MPH Professor of Pediatrics, University of Vermont - PowerPoint PPT Presentation


  • 134 Views
  • Uploaded on

Current Status of U.S. Pediatric Clinical Research Infrastructure: A Snapshot of Multi-Site Research Capacity. Richard C. “Mort” Wasserman, MD, MPH Professor of Pediatrics, University of Vermont Director, Pediatric Research in Office Settings (PROS) American Academy of Pediatrics.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Richard C. “Mort” Wasserman, MD, MPH Professor of Pediatrics, University of Vermont' - toby


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Current Status of U.S. Pediatric Clinical Research Infrastructure:A Snapshot of Multi-Site Research Capacity

Richard C. “Mort” Wasserman, MD, MPH

Professor of Pediatrics, University of Vermont

Director, Pediatric Research in Office Settings (PROS)

American Academy of Pediatrics

Work done with Eric Slora, PhD, Donna Harris, MA, and Alison Bocian, MS. Supported by the American Academy of Pediatrics

presentation objectives
Presentation Objectives
  • Explain focus on multi-site pediatric clinical research infrastructure
  • Provide a snapshot of pediatric clinical research network infrastructure
  • Provide a snapshot of pharmaceutical trials infrastructure
  • Offer some conclusions relevant to pediatric drug & medical device development
rationale for focus on multi site clinical research infrastructure
Rationale for Focus on Multi-Site Clinical Research Infrastructure
  • Pediatric clinical research often must recruit subjects from multiple sites, either because the clinical condition under study is uncommon, or because the study outcomes occur infrequently
  • Dictionary definition of infrastructure: “underlying foundation” or “basic framework”
  • Multi-site clinical research requires more of an infrastructure than single site research
multi method approach interviews
Multi-Method Approach: Interviews
  • Interviews: From February-July, 2007, we interviewed 33 pediatric clinical research experts on the topic of U.S pediatric clinical research capacity
  • Informant list:
    • developed to maximize cognitive diversity
    • refined during recruitment according to themes emerging in the interviews
  • Informants’ primary and secondary areas of expertise:
    • academician (21)
    • federal official (5)
    • industry medical officer (8)
    • pediatric research network leader (10)
    • pediatric specialist leader (8)
    • pediatric clinical pharmacologist (5)
    • practitioner-research site director (9)
multi method approach enumerating the exclusively pediatric clinical research networks
Multi-Method Approach:Enumerating the ExclusivelyPediatric Clinical Research Networks
  • Searched research network databases: IECRN & AHRQ-PBRN for exclusively pediatric networks
  • Identified additional networks:
    • Web search
    • Interview informants
  • Surveyed network contacts about past and current activities
multi method approach other surveys
Multi-Method Approach:Other Surveys
  • Survey of ~1,000 pediatric practitioners in PROS regarding pharmaceutical trials
  • Survey of 43 AAP subspecialty section and council leaders about clinical and pharmaceutical trials research among their members
slide7
Multi-Method Approach:Enumerating the Number of Sites in U.S. & Canada Participating in Pediatric Pharmaceutical Trials
  • Data from Clinicaltrials.gov
  • Data from FDA written requests
results pediatric clinical research networks
Results:Pediatric Clinical Research Networks
  • Types of networks (n=78)
    • Primary care (study topics are applicable to the general pediatric population): 22
    • Specialty (study topics are pertinent to a pediatric subspecialty such as oncology, rheumatology): 36
    • Disease-Specific (study topics are within a specific disease such as inflammatory bowel disease, type I diabetes): 20
results pediatric clinical research networks1
Results:Pediatric Clinical Research Networks
  • Network diversity:
    • Longevity (range 1-50+ years)
    • Geography
      • Regional (24%): national (30%); international (41%)
    • Types of studies:
      • Diagnostic test evaluation, variety of RCTs (patient and cluster level), registry, outcomes research, pharmacokinetics, qualitative research
    • Core funding: NIH, MCHB, AHRQ, foundations, institutional, none!
    • Number of publications: (range 0 - >1000)
    • ~ half entertain protocols from industry for pharmaceutical trials
results pediatric pharmaceutical research
Results:Pediatric Pharmaceutical Research
  • Qualitative analysis of interviews
    • dominant theme of insufficient pediatric drug trial capacity
      • lack of systems for finding, incentivizing, maintaining trial sites
      • complexity/demands of conducting drug trials in clinical settings
      • lack of qualified pediatric pharmacologists and clinician investigators trained in FDA Good Clinical Practice
      • poorly designed drug trial protocols that discourage pediatricians and parents from participating
results pediatric pharmaceutical research1
Results:Pediatric Pharmaceutical Research
  • Qualitative analysis of interviews
    • Potential solutions
      • Consensus-building among stakeholders to create pediatric pharmaceutical trial systems
      • Initiatives to train more pediatric pharmacologists and educate clinicians in Good Clinical Practice
      • Advocacy for high quality pharmaceutical protocols designed by scientists sensitive to pediatric issues
      • Pediatric and public education on the importance of pediatric pharmaceutical trials
slide12
Results:Enumerating the Number of Sites in U.S. & Canada Participating in Pediatric Pharmaceutical Trials
  • ???
bottom line
Bottom Line
  • Pediatric clinical research infrastructure relevant to pediatric drug & medical device development, although excellent in some areas, is inconsistently developed and highly fragmented
  • This meeting is a necessary step in correcting that situation